-+ 0.00%
-+ 0.00%
-+ 0.00%

Sumitomo Pharma, Novo Nordisk’s Wegovy wins Japan approval for MASH indication

PUBT·06/19/2026 05:15:50
Listen to the news
Sumitomo Pharma, Novo Nordisk’s Wegovy wins Japan approval for MASH indication
  • Japan cleared Wegovy (semaglutide 2.4 mg) for MASH without cirrhosis in patients with F2-F3 fibrosis under Novo Nordisk Pharma’s authorization.
  • Sumitomo Pharma will co-promote the once-weekly GLP-1 drug in Japan, expanding its partnership with Novo Nordisk Pharma beyond obesity.
  • Approval relied on Phase 3 ESSENCE data at week 72: fibrosis improvement 36.8% vs 22.4% placebo; MASH resolution 62.9% vs 34.3%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on June 19, 2026, and is solely responsible for the information contained therein.